.

Pharmaceutical Business Intelligence

  • Anticipate P&T budget requirements
  • Evaluate market entry opportunities
  • Find generic sources and suppliers
  • Predict branded drug patent expiration

► Plans and Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

DrugPatentWatch Database Preview

Details for Patent: 6,479,055

« Back to Dashboard

Details for Patent: 6,479,055

Title: Methods for inhibition of membrane fusion-associated events, including respiratory syncytial virus transmission
Abstract:The present invention relates to peptides which exhibit potent anti-viral activity. In particular, the invention relates to methods of using such peptides as inhibitory of respiratory syncytial virus ("RSV") transmission to uninfected cells. The peptides used in the methods of the invention are homologs of the DP-178 and DP-107 peptides, peptides corresponding to amino acid residues 638 to 673, and to amino acid residues 558 to 595, respectively, of the HIV-1.sub.LAI transmembrane protein (TM) gp41.
Inventor(s): Bolognesi; Dani Paul (Durham, NC), Matthews; Thomas James (Durham, NC), Wild; Carl T. (Durham, NC), Barney; Shawn O'Lin (Cary, NC), Lambert; Dennis Michael (Cary, NC), Petteway; Stephen Robert (Cary, NC), Langlois; Alphonse J. (Durham, NC)
Assignee: Trimeris, Inc. (Durham, NC)
Filing Date:Jun 06, 1995
Application Number:08/470,896
Claims:1. A method for inhibiting transmission of a respiratory syncytial virus to a cell, said method comprising contacting said cell with an effective concentration of an isolated peptide for an effective period of time; wherein said isolated peptide comprises an amino acid sequence of a respiratory syncytial virus protein; wherein said isolated peptide is identified by one or more of an ALLMOTI5, 107.times.178'4 and PLZIP sequence search motifs; and wherein fusion of the virus to the cell is inhibited.

2. A method for inhibiting transmission of a respiratory syncytial virus to a cell, said method comprising contacting said cell with an effective concentration of an isolated peptide; wherein said isolated peptide has the formula: X-TSVITIELSNIKENKCNGTDAKVKLIKQELDKYKN-Z; X-SVITIELSNIKENKCNGTDAKVKLIKQELDKYKNA-Z; X-VITIELSNIKENKCNGTDAKVKLIKQELDKYKNAV-Z; X-VAVSKVLHLEGEVNKIALLSTNKAVVSLSNGVS-Z; X-AVSKVLHLEGEVNKIALLSTNKAVVSLSNGVSV-Z; X-VSKVLHLEGEVNKIALLSTNKAVVSLSNGVSVL-Z; X-SKVLHLEGEVNKIALLSTNKAVVSLSNGVSVLT-Z; X-KVLHLEGEVNKIALLSTNKAVVSLSNGVSVLTS-Z; X-LEGEVNKIALLSTNKAVVSLSNGVSVLTSKVLD-Z; X-GEVNKIALLSTNKAVVSLSNGVSVLTSKVLDLK-Z; X-EVNKIALLSTNKAVVSLSNGVSVLTSKVLDLKN-Z; X-VNKIALLSTNKAVVSLSNGVSVLTSKVLDLKNY-Z; X-NKIALLSTNKAVVSLSNGVSVLTSKVLDLKNYI-Z; X-KIALLSTNKAVVSLSNGVSVLTSKVLDLKNYID-Z; X-IALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDK-Z; X-ALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQ-Z; X-VAVSKVLHLEGEVNKIALLSTNKAVVSLSNGVS-Z; X-AVSKVLHLEGEVNKIALLSTANKVVSLSNGVSV-Z; X-VSKVLHLEGEVNKIALLSTNKAVVSLSNGVSVL-Z; X-SKVLHLEGEVNKIALLSTNKAVVSLSNGVSVLT-Z; X-KVLHLEGEVNKIALLSTNKAVVSLSNGVSVLTS-Z; X-LEGEVNKIALLSTNKAVVSLSNGVSVLTSKVLD-Z; X-GEVNKIALLSTNKAVVSLSNGVSVLTSKVLDLK-Z; X-EVNKIALLSTNKAVVSLSNGVSVLTSKVLDLKN-Z; X-VNKIALLSTNKAVVSLSNGVSVLTSKVLDLKNY-Z: X-NKIALLSTNKAVVSLSNGVSVLTSKVLDLKNYI-Z; X-KIALLSTNKAVVSLSNGVSVLTSKLDLKCNYID-Z; or X-IALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDK-Z, (SEQ ID NOS:210-237, respectively); in which: amino acid residues are presented by the single-letter code; X comprises the amino group of said peptide, an acetyl group, a 9-fluorenylmethoxy carbonyl group, a hydrophobic group, or a macromolecule carrier group; Z comprises the carboxyl group of said peptide, an amido group, a hydrophobic group, or a macromolecular carrier group; and wherein fusion of said virus to said cell is inhibited.

3. The method of claim 2, wherein said peptide has the formula: X-TSVITIELSNIKENKCNGTDAKVKLIKQELDKYKN-Z (SEQ ID NO:210).

4. The method of claim 2, wherein said peptide has the formula: X-SVITIELSNIKENKCNGTDAKVKLIKQELDKYKNA-Z (SEQ ID NO:211).

5. The method of claim 2, wherein said peptide has the formula: X-VITIELSNIKENKCNGTDAKVKLIKQELDKYKNAV-Z (SEQ ID NO:212).

6. The method of claim 2, wherein said peptide has the formula: X-VAVSKVLHLEGEVNKIALLSTNKAVVSLSNGVS-Z (SEQ ID NO:213).

7. The method of claim 2, wherein said peptide has the formula: X-AVSKVLHLEGEVNKIALLSTNKAVVSLSNGVSV-Z (SEQ ID NO:214).

8. The method of claim 2, wherein said peptide has the formula: X-VSKVLHLEGEVNKIALLSTNKAVVSLSNGVSVL-Z (SEQ ID NO:215).

9. The method of claim 2, wherein said peptide has the formula: X-SKVLHLEGEVNKIALLSTNKAVVSLSNGVSVLT-Z (SEQ ID NO:216).

10. The method of claim 2, wherein said peptide has the formula: X-KVLHLEGEVNKIALLSTNKAVVSLSNGVSVLTS-Z (SEQ ID NO:217).

11. The method of claim 2, wherein said peptide has the formula: X-LEGEVNKIALLSTNKAVVSLSNGVSVLTSKVLD-Z (SEQ ID NO:218).

12. The method of claim 2, wherein said peptide has the formula: X-GEVNKIALLSTNKAVVSLSNGVSVLTSKVLDLK-Z (SEQ ID NO:219).

13. The method of claim 2, wherein said peptide has the formula: X-EVNKIALLSTNKAVVSLSNGVSVLTSKVLDLKN-Z (SEQ ID NO:220).

14. The method of claim 2, wherein said peptide has the formula: X-VNKIALLSTNKAVVSLSNGVSVLTSKVLDLKNY-Z (SEQ ID NO:221).

15. The method of claim 2, wherein said peptide has the formula: X-NKIALLSTNKAVVSLSNGVSVLTSKVLDLKNYI-Z (SEQ ID NO:222).

16. The method of claim 2, wherein said peptide has the formula: X-KIALLSTNKAVVSLSNGVSVLTSKVLDLKNYID-Z (SEQ ID NO:223).

17. The method of claim 2, wherein said peptide has the formula: X-IALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDK-Z (SEQ ID NO:224).

18. The method of claim 2, wherein said peptide has the formula: X-ALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDKQ-Z (SEQ ID NO:225).

19. The method of claim 2, wherein said peptide has the formula: X-VAVSKVLHLEGEVNKIALLSTNKAVVSLSNGVS-Z (SEQ ID NO:226).

20. The method of claim 2, wherein said peptide has the formula: X-AVSKVLHLEGEVNKIALLSTNKAVVSLSNGVSV-Z (SEQ ID NO:227).

21. The method of claim 2, wherein said peptide has the formula: X-VSKVLHLEGEVNKIALLSTNKAVVSLSNGVSVL-Z (SEQ ID NO:228).

22. The method of claim 2, wherein said peptide has the formula: X-SKVLHLEGEVNKIALLSTNKAVVSLSNGVSVLT-Z (SEQ ID NO:229).

23. The method of claim 2, wherein said peptide has the formula: X-KVLHLEGEVNKIALLSTNKAVVSLSNGVSVLTS-Z (SEQ ID NO:230).

24. The method of claim 2, wherein said peptide has the formula: X-LEGEVNKIALLSTNKAVVSLSNGVSVLTSKVLD-Z (SEQ ID NO:231).

25. The method of claim 2, wherein said peptide has the formula: X-GEVNKIALLSTNKAVVSLSNGVSVLTSKVLDLK-Z (SEQ ID NO:232).

26. The method of claim 2, wherein said peptide has the formula: X-EVNKIALLSTNKAVVSLSNGVSVLTSKVLDLKN-Z (SEQ ID NO:233).

27. The method of claim 2, wherein said peptide has the formula: X-VNKIALLSTNKAVVSLSNGVSVLTSKVLDLKNY-Z (SEQ ID NO:234).

28. The method of claim 2, wherein said peptide has the formula: X-NKIALLSTNKAVVSLSNGVSVLTSKVLDLKNYI-Z (SEQ ID NO:235).

29. The method of claim 2, wherein said peptide has the formula: X-KIALLSTNKAVVSLSNGVSVLTSKVLDLKNYID-Z (SEQ ID NO:236).

30. The method of claim 2, wherein said peptide has the formula: X-IALLSTNKAVVSLSNGVSVLTSKVLDLKNYIDK-Z (SEQ ID NO:237).

31. The method of claim 1, wherein said peptide is 28 amino acid residues in length and is identified by the ALLMOTI5 motif.

32. The method of claim 1, wherein said peptide is 35 amino acid residues in length and is identified by the ALLMOTI5 motif.

33. The method of claim 1, wherein said peptide is 28 amino acid residues in length and is identified by the 107.times.178.times.4 motif.

34. The method of claim 1, wherein said peptide is 35 amino acid residues in length and is identified by the 107.times.178.times.4 motif.

35. The method of claim 1, wherein said peptide is identified by a PLZIP motif.

36. The method of claim 2 wherein X is a macromolecular carrier group.

37. The method of claim 36 wherein the macromolecular carrier group X is a peptide group.

38. The method of claim 37 wherein said peptide group is 2 to 50 respiratory syncytial virus protein amino acid residues amino to said isolated peptide.

39. The method of claim 2 wherein Z is a macromolecular carrier group.

40. The method of claim 39 wherein the macromolecular carrier group Z is a peptide group.

41. The method of claim 40 wherein said peptide group is about 2 to about 50 respiratory syncytial virus protein amino acid residues carboxy to said isolated peptide.

42. The method of claim 41 wherein X is a macromolecular carrier group, said macromolecular carrier group X being a peptide group of 2 to 50 respiratory syncytial virus protein amino acid residues amino to said isolated peptide.

43. A method for inhibiting transmission of a respiratory syncytial virus to a cell, said method comprising contacting the cell with an effective concentration of an isolated peptide for an effective period of time; wherein said peptide consists of an amino acid sequence of a respiratory syncytial virus protein; wherein said peptide is identified by one or more of an ALLMOTI5, 107.times.178.times.4 and PLZIP sequence search motifs; and wherein fusion of the virus to the cell in inhibited.

44. A method for inhibiting transmission of a respiratory syncytial virus to a cell, said method comprising contacting the cell with an effective concentration of an isolated peptide for an effective period of time; wherein said peptide consists of an amino acid sequence of a respiratory syncytial virus protein; wherein said peptide is identified by one or more of an ALLMOTI5, 107.times.178.times.4 and PLZIP sequence search motifs; wherein said peptide further comprises an amino terminal X, and a carboxy terminal Z in which X comprises the amino group of said peptide, an acetyl group, a 9-fluorenylmethoxy- carbonyl group, a hydrophobic group or a macromolecular carrier group, and Z comprises the carboxyl group of said peptide, an amido group, a hydrophobic group or a macromolecular carrier group; and wherein fusion of the virus to the cell in inhibited.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

`abc